InsidersTradesSigma
Total declarations
Company
▲ Purchases (22 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
22
Disclosed sells
0
T+90 hit rate
50%
T+90 mean return
+10.4%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Weisblum Eric, Chief Executive Officer. Officer active across 1 company, notably Silo Pharma, Inc.. Aggregated, 23 filings have been logged. Breakdown: 22 buys · 0 sell. Total volume traded: €40k. Activity tracked since 17 June 2019. The latest transaction was disclosed on 15 December 2025 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Weisblum Eric
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations23 total
2,500 shares@ US$0.412.4% of flowCommon StockSEC:0001213900-25-122429:0
Canonical exit: 15 Mar 2026 (T+90)
1,000 shares@ US$0.370.9% of flowCommon StockSEC:0001213900-25-113743:0
Canonical exit: 18 Feb 2026 (T+90)
7,500 shares@ US$0.40337.5% of flowCommon StockSEC:0001213900-25-113104:0
Canonical exit: 16 Feb 2026 (T+90)
10,000 shares@ US$0.43299.6% of flowCommon StockSEC:0001213900-25-048304:0
Canonical exit: 25 Aug 2025 (T+90)
2,500 shares@ US$0.83876.1% of flowCommon StockSEC:0001213900-24-109363:0
Canonical exit: 13 Mar 2025 (T+90)
2,500 shares@ US$0.956.8% of flowCommon StockSEC:0001213900-24-101610:0
Canonical exit: 18 Feb 2025 (T+90)
562 shares@ US$1.081.7% of flowCommon StockSEC:0001213900-24-052354:0
Canonical exit: 9 Sept 2024 (T+90)
600 shares@ US$1.963.3% of flowCommon StockSEC:0001213900-24-031159:0
Canonical exit: 3 Jul 2024 (T+90)
3,408 shares@ US$1.9418.6% of flowCommon StockSEC:0001213900-24-028973:0
Canonical exit: 26 Jun 2024 (T+90)
500 shares@ US$1.632.3% of flowCommon StockSEC:0001213900-23-097689:0
Canonical exit: 18 Mar 2024 (T+90)
200 shares@ US$1.500.8% of flowCommon StockSEC:0001213900-23-096606:0
Canonical exit: 13 Mar 2024 (T+90)
600 shares@ US$1.392.3% of flowCommon StockSEC:0001213900-23-094145:0
Canonical exit: 4 Mar 2024 (T+90)
1,000 shares@ US$1.574.3% of flowCommon StockSEC:0001213900-23-091665:0
Canonical exit: 27 Feb 2024 (T+90)
400 shares@ US$1.681.9% of flowCommon StockSEC:0001213900-23-090270:0
Canonical exit: 20 Feb 2024 (T+90)
4,050 shares@ US$1.6018.1% of flowCommon StockSEC:0001213900-23-089570:0
Canonical exit: 18 Feb 2024 (T+90)
1,100 shares@ US$1.334.1% of flowCommon StockSEC:0001213900-23-088890:0
Canonical exit: 14 Feb 2024 (T+90)
2,500 shares@ US$2.0614.5% of flowCommon StockSEC:0001213900-23-041179:0
Canonical exit: 15 Aug 2023 (T+90)
200 shares@ US$2.68151.5% of flowCommon StockSEC:0001213900-22-081513:0
Canonical exit: 19 Mar 2023 (T+90)
487 shares@ US$3.06764.3% of flowCommon StockSEC:0001213900-22-080102:0
Canonical exit: 13 Mar 2023 (T+90)
13,080 shares@ US$0.11470.022% mcap47.4% of flowCommon StockSEC:0001213900-22-033752:0
Canonical exit: 15 Sept 2022 (T+90)
5,000 shares@ US$0.15541.7% of flowCommon StockSEC:0001213900-21-065395:0
Canonical exit: 10 Mar 2022 (T+90)
57,714 shares@ US$0.0020.3% of flowCommon StockSEC:0001213900-21-026675:0
Canonical exit: 15 Sept 2019 (T+90)
7,630,949 sharesCommon StockSEC:0001213900-21-026677:0
23 of 23 declarations
About Weisblum Eric
Weisblum Eric is Directeur Général and Chief Executive Officer at Silo Pharma, Inc. He has 23 filings in total, and across the 23 sampled filings the transactions are acquisitions totaling EUR 39,638, with activity from 2021-05-17 to 2025-12-16.
